Formula #12
What is Formula #12?
This product is a unique combination of soy lecithin, alpha lipoic acid, lemon oil and other identified binding agents. It looks like peanut butter, comes in a squeeze tube, and is taken four times a day on an empty stomach. A small ball, about the size of a chickpea or small marble, is squeezed out and swallowed whole with some water. It may be possible in the future to make a capsule, but this is not currently possible. This food product does not need refrigeration.
The Science
Formula #12 is a complex mixture of soy lecithin and alpha lipoic acid (along with a few other supporting ingredients such as lemon oil). What Formula #12 designers accomplished was to develop a cell membrane transporter (using soy lecithin phospholipid) in concert with a way to bind it to the alpha lipoic acid as a well-known detoxifying agent. Formula #12 can pass the blood-brain barrier and remove the build-up of hydrogen peroxide from the mitochondria of the cells - the heart(s) of the cells - so that the cells can once again function reasonably normally. In the case of dopamine producing cells, this means that the natural production again of dopamine for the PD patient, thereby aiding the patient's physiology to operate to an improved degree. From this internal production of dopamine, accrues improved quality of life while presenting no side effects or adverse conditions. At the present time, the Formula #12 designers have been producing limited quantities of Formula #12 and have been undertaking case studies over a two year period to elucidate the quality of life expectations of these case study participants. Neither Evans nor TRI has any financial connection with Formula #12, its designers, nor with any economic outcomes of this research.
Selected Case Studies
Case Study #1:
This participant has been on Formula #12 for three months after following the more complicated original formulation for about three months. Since he terminated his levadopa medications after about the initial two weeks, his continued excellent outcome likely indicates that cellular detoxification permits restoration of dopamine production to an adequate extent.
Cast Study #2:
This individual suffered from ever increasing PD disabilities although he had elected to take no medications prior to his trial participation. He has been on Formula #12 for several months and has observed the nearly complete dissipation of his symptoms. One is led to the probable conclusion that Formula #12 can restore quality of life to a PD patient.
Case Study #3:
The participant was taking traditional medication but failed to constrain numerous PD symptoms. After the first week, symptoms were reduced, after the second week, symptoms were substantially abated, and by the third week, extraordinary symptom relief was obtained and has continued. He is on his second month of participation.
Another several similar case studies are also available.
